Hang Liu1, Cory A Perugino2, Musie Ghebremichael3, Zachary S Wallace4, Sydney B Montesi4, John H Stone4, Shiv Pillai3. 1. Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, and First Affiliated Hospital of China Medical University, Shenyang, China. 2. Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, and Massachusetts General Hospital, Boston. 3. Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts. 4. Massachusetts General Hospital, Boston.
Abstract
OBJECTIVE: Four autoantigens have been described recently in IgG4-related disease (IgG4-RD): prohibitin, annexin A11, laminin 511-E8, and galectin-3. However, no external validation has been performed, and the possibility that some individuals break tolerance to more than 1 autoantigen has not been explored. We undertook this study to evaluate the relative frequencies of antibody responses against these autoantigens in order to explore the role of adaptive immune response in IgG4-RD. METHODS: Autoantibody responses against prohibitin, annexin A11, and laminin 511-E8 were measured among a clinically diverse cohort of IgG4-RD patients (n = 100) using enzyme-linked immunosorbent assays. Autoantibody responses were correlated with disease severity and organ distribution. RESULTS: The frequencies of IgG4 autoantibody responses against prohibitin (10%), annexin A11 (12%), and laminin 511-E8 (7%) were not significantly different from those of controls. A portion of the cohort (n = 86) had been analyzed previously at our center for anti-galectin-3 antibody responses, with 25 patients (29%) having IgG4 anti-galectin-3 antibodies. Of these 86 patients, 32 (37%) had IgG4 antibodies to ≥1 of the 4 autoantigens and 12 (14%) showed reactivity with ≥2 of the tested antigens. The subset of patients with ≥2 autoantibodies had higher total levels of IgG1, IgG2, IgG4, and C-reactive protein, were more commonly hypocomplementemic, and were more likely to have visceral organ involvement. CONCLUSION: Antibodies against prohibitin, annexin A11, and laminin 511-E8 were found in only a small portion of patients with IgG4-RD. A subset of IgG4-RD patients, however, had IgG4 antibodies against ≥2 autoantigens. These patients presented with robust IgG subclass elevations, complement consumption, and visceral organ involvement. This broader break in immunologic tolerance in IgG4-RD was associated with more severe disease.
OBJECTIVE: Four autoantigens have been described recently in IgG4-related disease (IgG4-RD): prohibitin, annexin A11, laminin 511-E8, and galectin-3. However, no external validation has been performed, and the possibility that some individuals break tolerance to more than 1 autoantigen has not been explored. We undertook this study to evaluate the relative frequencies of antibody responses against these autoantigens in order to explore the role of adaptive immune response in IgG4-RD. METHODS: Autoantibody responses against prohibitin, annexin A11, and laminin 511-E8 were measured among a clinically diverse cohort of IgG4-RD patients (n = 100) using enzyme-linked immunosorbent assays. Autoantibody responses were correlated with disease severity and organ distribution. RESULTS: The frequencies of IgG4 autoantibody responses against prohibitin (10%), annexin A11 (12%), and laminin 511-E8 (7%) were not significantly different from those of controls. A portion of the cohort (n = 86) had been analyzed previously at our center for anti-galectin-3 antibody responses, with 25 patients (29%) having IgG4 anti-galectin-3 antibodies. Of these 86 patients, 32 (37%) had IgG4 antibodies to ≥1 of the 4 autoantigens and 12 (14%) showed reactivity with ≥2 of the tested antigens. The subset of patients with ≥2 autoantibodies had higher total levels of IgG1, IgG2, IgG4, and C-reactive protein, were more commonly hypocomplementemic, and were more likely to have visceral organ involvement. CONCLUSION: Antibodies against prohibitin, annexin A11, and laminin 511-E8 were found in only a small portion of patients with IgG4-RD. A subset of IgG4-RD patients, however, had IgG4 antibodies against ≥2 autoantigens. These patients presented with robust IgG subclass elevations, complement consumption, and visceral organ involvement. This broader break in immunologic tolerance in IgG4-RD was associated with more severe disease.
Authors: Mollie N Carruthers; Mark D Topazian; Arezou Khosroshahi; Thomas E Witzig; Zachary S Wallace; Philip A Hart; Vikram Deshpande; Thomas C Smyrk; Suresh Chari; John H Stone Journal: Ann Rheum Dis Date: 2015-02-09 Impact factor: 19.103
Authors: Emanuel Della-Torre; Eoin Feeney; Vikram Deshpande; Hamid Mattoo; Vinay Mahajan; Maria Kulikova; Zachary S Wallace; Mollie Carruthers; Raymond T Chung; Shiv Pillai; John H Stone Journal: Ann Rheum Dis Date: 2014-08-20 Impact factor: 19.103
Authors: Ruyu Qi; Luke Y C Chen; Sujin Park; Robert Irvine; Michael A Seidman; John T Kelsall; David Collins; Vivian Yin; Graham W Slack; Andre Mattman; Eric Lam; Mollie N Carruthers Journal: Am J Med Sci Date: 2017-08-24 Impact factor: 2.378
Authors: Shounak Majumder; Sonmoon Mohapatra; Ryan J Lennon; Guilherme Piovezani Ramos; Neil Postier; Ferga C Gleeson; Michael J Levy; Randall K Pearson; Bret T Petersen; Santhi Swaroop Vege; Suresh T Chari; Mark D Topazian; Thomas E Witzig Journal: Clin Gastroenterol Hepatol Date: 2018-03-08 Impact factor: 11.382
Authors: Hyon K Choi; John H Stone; Zachary S Wallace; Yuqing Zhang; Cory A Perugino; Ray Naden Journal: Ann Rheum Dis Date: 2019-01-05 Impact factor: 19.103
Authors: Cory A Perugino; Hamid Mattoo; Vinay S Mahajan; Takashi Maehara; Zachary S Wallace; Shiv Pillai; John H Stone Journal: Arthritis Rheumatol Date: 2017-08-08 Impact factor: 10.995
Authors: Marieke E Doorenspleet; Lowiek M Hubers; Emma L Culver; Lucas J Maillette de Buy Wenniger; Paul L Klarenbeek; Roger W Chapman; Frank Baas; Stan F van de Graaf; Joanne Verheij; Thomas M van Gulik; Eleanor Barnes; Ulrich Beuers; Niek de Vries Journal: Hepatology Date: 2016-06-08 Impact factor: 17.425
Authors: Hugues Allard-Chamard; Faisal Alsufyani; Naoki Kaneko; Kelly Xing; Cory Perugino; Vinay S Mahajan; Joseph L Wheat; George S Deepe; James Loyd; Shiv Pillai Journal: J Immunol Date: 2020-12-16 Impact factor: 5.422
Authors: Jiachen Liu; Wei Yin; Lisa S Westerberg; Pamela Lee; Quan Gong; Yan Chen; Lingli Dong; Chaohong Liu Journal: Front Immunol Date: 2021-09-01 Impact factor: 7.561
Authors: David Faz-Muñoz; Andrea Hinojosa-Azaola; Juan M Mejía-Vilet; Norma O Uribe-Uribe; Marina Rull-Gabayet; Wallace Rafael Muñoz-Castañeda; Nancy Janeth Vargas-Parra; Eduardo Martín-Nares Journal: Immunol Res Date: 2022-04-21 Impact factor: 4.505
Authors: Michelle D Catalina; Prathyusha Bachali; Anthony E Yeo; Nicholas S Geraci; Michelle A Petri; Amrie C Grammer; Peter E Lipsky Journal: JCI Insight Date: 2020-08-06